Clinical Trials · NCT07770282
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Enrollment
- 600
- Start date
- Dec 2026
- Locations
- See registry
- Primary endpoint
- Change in QRISK3 (QResearch Cardiovascular Risk Prediction Algorithm Version 3),10-year cardiovascular risk score